The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...
Johnson & Johnson (J&J), formed in 1886, is a prominent American multinational corporation known for medical devices, pharmaceuticals, and consumer packaged goods. The company distinguishes itself ...
Johnson & Johnson, founded in 1886, makes and sells medical devices, pharmaceuticals, and consumer health products. Headquartered in New Brunswick, N.J., the company operates over 250 subsidiary ...
Despite CVS Health's issues, its prospects and solid dividend program make it attractive for income seekers. Johnson & ...
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...
Leerink Partners analyst Marc Goodman has maintained their bullish stance on JNJ stock, giving a Buy rating on January 8.Stay Ahead of the ...
Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest ...
Connected medical devices can dramatically improve how ... A few months later, Johnson & Johnson warned 114,000 customers that its Animus OneTouch Ping insulin pump had a security flaw that ...